A presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 15, 2007

Presenters

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Mohammad Jahanzeb, MD
St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute
Memphis, Tennessee

Faculty Disclosure Statements

David S. Ettinger, MD

Dr. Ettinger has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a paid speaker for Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., Merck & Co., Inc., and MGI PHARMA, Inc. Additionally, he has received grant and/or research support for his roles as principal investigator for Bristol-Myers Squibb Company, Genentech, Inc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Sunesis Pharmaceuticals, Inc., and sanofi-aventis U.S. Dr. Ettinger has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.

Mohammad Jahanzeb, MD

Dr. Jahanzeb has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He receives grant or research support from Amgen Inc., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, and sanofi-aventis U.S. Dr. Jahanzeb also serves on speakers’ bureaus for Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, and sanofi-aventis U.S. Dr. Jahanzeb is an advisory board member for AstraZeneca Pharmaceuticals LP, Eisai Inc., Eli Lilly and Company, Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc. Dr. Jahanzeb has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.

Program Overview

This presentation will focus on the rationale behind the latest changes to the NCCN Non-Small Cell Lung Cancer Guidelines. Guidelines for screening, adjuvant therapy for stage I and II disease, management of stage III disease, and chemotherapy and targeted therapy for stage IV and recurrent disease will be discussed.

Educational Objectives

Following this activity, participants should be able to:

Discuss updates to the NCCN guidelines for non-small cell lung cancer
Explain how these updates will impact management of non-small cell lung cancer care

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 16, 2008. There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category
1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date: May 16, 2007
Expiration date: May 16, 2008

Commercial Support

Distribution supported by educational grants from Eli Lilly and Company and Genentech BioOncology/OSI Pharmaceuticals

Mark A A Size

Find information for: